Protecting Patient Access to Cancer and Complex Therapies Act
- Sponsor
- Rep. Murphy, Gregory F. [R-NC-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 7, 2025
Bottom line
The bill implements drug price negotiation for Medicare Part B selected drugs through a manufacturer rebate mechanism, aiming to ensure patients benefit from lower negotiated prices at the point of sale while maintaining the existing ASP+6 payment structure for providers.
What it actually does
This bill amends Medicare Part B drug payment rules by requiring pharmaceutical manufacturers to pay a rebate for selected drugs subject to maximum fair price (MFP) negotiation. Instead of directly paying for these drugs at the negotiated MFP, Medicare Part B will continue to pay providers based on the average sales price plus 6% (ASP+6). Manufacturers will then rebate the difference between the ASP+6 payment (minus beneficiary coinsurance) and the MFP+6 payment (minus beneficiary coinsurance) back to the government. Crucially, beneficiary coinsurance will be calculated based on the lower MFP+6 amount, reducing out-of-pocket costs for patients.
Proponents argue
Supporters argue this approach preserves the existing Medicare Part B payment system for providers, which they contend is crucial for maintaining patient access to complex and cancer therapies administered in physician offices and hospitals. They believe it ensures that providers are reimbursed adequately, preventing potential disruptions in care while still delivering the cost savings and lower patient out-of-pocket expenses intended by drug price negotiation.
Opponents contend
Opponents might argue that this rebate mechanism adds unnecessary complexity to the drug pricing system, potentially creating administrative burdens for manufacturers and the government. They could also contend that it deviates from the more direct price reduction model envisioned by the original drug price negotiation legislation, potentially leading to less transparency or slower realization of savings.
The bill is relatively short, but its technical nature and reliance on existing Social Security Act provisions make it moderately complex to fully grasp within a short timeframe.
Section 2(a), amending Section 1847A(b)(1)(B) of the Social Security Act
Maintaining Payments Under Part B Based on ASP+6 for Selected Drugs
This provision removes the exception that would have caused 'selected drugs' (those subject to maximum fair price negotiation) to be paid differently under Medicare Part B. Instead, it ensures that payment for these drugs to providers will continue to be based on the average sales price plus 6% (ASP+6), the standard payment methodology for most Part B drugs. This means providers will not see a direct reduction in their reimbursement for these specific drugs.
Supporters argue
Supporters argue that maintaining the ASP+6 payment structure for providers is essential to ensure they can continue to acquire and administer selected drugs without financial disincentives, thereby protecting patient access to critical therapies, especially for cancer and complex conditions.
Critics contend
Opponents might argue that this provision complicates the drug pricing system by separating the negotiated price from the payment to providers, potentially reducing transparency and adding administrative layers compared to a direct price reduction.
Tradeoffs
This provision balances the goal of reducing drug costs (through negotiation) with the concern of maintaining provider financial stability and patient access. It prioritizes provider reimbursement stability over a simpler, direct price reduction at the point of sale.
Section 2(b)(1), inserting new Subsection (j) into Section 1847A of the Social Security Act
Manufacturer Rebate for Selected Drugs Subject to Maximum Fair Price Negotiation
This is the core of the bill, establishing a new requirement for manufacturers of selected drugs. For each calendar quarter, manufacturers must pay a rebate to the Secretary. The rebate amount is calculated as the difference between the ASP+6 payment amount (minus beneficiary coinsurance) and the MFP+6 payment amount (minus beneficiary coinsurance), multiplied by the total units of the drug furnished under Part B. This rebate is in addition to any other existing rebates.
Section 2(b)(1), new Subsection (j)(2) of Section 1847A of the Social Security Act
Calculation of Beneficiary Coinsurance Based on MFP+6
This provision directly benefits Medicare beneficiaries by stipulating that their coinsurance for selected drugs subject to the new rebate will be calculated based on the lower Maximum Fair Price plus 6% (MFP+6) amount, rather than the higher Average Sales Price plus 6% (ASP+6) amount. This means patients will pay less out-of-pocket for these drugs.
Section 2(b)(1), new Subsection (j)(3) of Section 1847A of the Social Security Act
Rebate Deposits into Federal Supplementary Medical Insurance Trust Fund
This provision specifies that all amounts collected from manufacturers as rebates under this new subsection will be deposited into the Federal Supplementary Medical Insurance Trust Fund. This fund is primarily used to pay for Medicare Part B benefits.
Section 2(b)(1), new Subsection (j)(4) of Section 1847A of the Social Security Act
Civil Money Penalty for Non-Compliance
This provision extends an existing civil money penalty (CMP) for non-compliance with drug rebate requirements to cover failures to comply with the new rebate mechanism established by this bill. Specifically, it applies the same penalty that exists for failures related to inflation rebates to manufacturers who do not provide the required rebates for selected drugs.
Section 2(b)(7), amending Section 1193(a) of the Social Security Act
Inclusion of New Rebate in Manufacturer Agreements
This provision amends the requirements for agreements that manufacturers must have with the Secretary of Health and Human Services to include the payment of rebates in accordance with the new Section 1847A(j). This formalizes the manufacturer's obligation to participate in the rebate program as a condition of their drugs being covered by Medicare.
This clarification explicitly states that nothing in the relevant sections (Part E of title XI or this new subsection) should be interpreted to require a manufacturer to provide selected drugs at maximum fair prices other than through the rebate mechanism. This means the bill does not mandate a direct price reduction at the point of sale for providers.
Section 2(b)(1), new Subsection (j)(6) of Section 1847A of the Social Security Act
Why it matters:This is a critical operational detail that defines the fundamental mechanism of the bill. It's buried because it clarifies that the bill's approach is a rebate, not a direct price control on providers. This distinction is central to the bill's strategy of maintaining ASP+6 payments for providers, which is a politically sensitive point. It could be seen as standard legislative practice to clarify scope, but its placement might also serve to de-emphasize this structural choice.
Case for: Supporters would argue this clarification is essential for transparency, explicitly stating that the bill's intent is to use a rebate system to capture savings, thereby protecting providers from direct payment cuts and potential disruptions to patient access.
Case against: Critics might argue that by explicitly stating that manufacturers are not required to provide drugs at MFP directly, the bill entrenches a more complex system than a direct price reduction, potentially making the overall drug pricing landscape less straightforward.
Estimated impact: This provision confirms the bill's structural choice to implement negotiated prices via a rebate, impacting the administrative burden on manufacturers and the payment flow for Medicare, rather than altering the direct payment rate to providers.
This provision amends the calculation of Average Sales Price (ASP) to explicitly exclude the new manufacturer rebates established under subsection (j). This prevents the rebates from artificially lowering the reported ASP, which is used for various other payment calculations in Medicare Part B.
Section 2(b)(5), amending Section 1847A(c)(3) of the Social Security Act
Why it matters:This is a standard technical adjustment to prevent unintended consequences in complex payment formulas. If the rebates were included in ASP calculations, it could distort the reported ASP, potentially affecting payments for other drugs or other aspects of the Medicare program. Its burial is standard legislative practice for technical corrections.
Case for: Supporters would argue this is a necessary technical fix to ensure the integrity of the ASP calculation, preventing unintended distortions that could arise from including the new rebates.
Case against: No specific opposition is typically raised against technical corrections that maintain the accuracy of payment formulas, though some might argue that the complexity of the overall system necessitates such frequent adjustments.
Estimated impact: Ensures that the ASP, a foundational metric for Medicare Part B drug payments, remains accurate and is not skewed by the new rebate program, thereby maintaining predictability for other drug pricing mechanisms.